Navigation Links
BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results
Date:2/17/2011

SHEETSDecember 31, 2010 and 2009(In thousands of U.S. dollars, except share and per share amounts)December 31, 2010 December 31, 2009 (1)(unaudited)ASSETSCurrent assets:Cash and cash equivalents$

88,079$

167,171Short-term investments186,033133,506Accounts receivable, net86,57673,540Inventory109,69878,662Other current assets33,87414,848Total current assets504,260467,727Investment in BioMarin/Genzyme LLC1,082441Long-term investments128,171169,849Property, plant and equipment, net221,866199,141Intangible assets, net103,64840,977Goodwill53,36423,722Long-term deferred tax assets236,017-Other assets14,21515,306Total assets$

1,262,623$

917,163LIABILITIES AND STOCKHOLDERS’ EQUITYCurrent liabilities:Accounts payable and accrued liabilities$

83,632$

78,068Deferred revenue21286Total current liabilities83,84478,154Convertible debt377,521497,083Other long-term liabilities84,00119,741Total liabilities545,366594,978Stockholders’ equity:Common stock, $0.001 par value: 250,000,000 shares authorized at December 31, 2010 and 2009;
,634,465 and 100,961,922 shares issued and outstanding at December 31, 2010 and 2009,
respectively111101Additional paid-in capital1,090,188899,950Company common stock held by Nonqualified Deferred Compensation Plan(1,965)(1,715)Accumulated other comprehensive income (loss)188933Accumulated deficit(371,265)(577,084)Total stockholders’ equity717,257322,185Total liabilities and stockholders’ equity$

1,262,623$

917,163(1) December 31, 2009 balances were derived from the audited consolidated financial statements.BIOMARIN PHARMACEUTICAL INC.CONSOLIDATED STATEMENTS OF OPERATIONSFor the Three and Twelve Months Ended December 31, 2010 and 2009(In thousands, except for per share data)Three Months Ended December 31,Twelve Months Ended December 31,2010(unaudited)2009(unaudited)2010(unaudited)2009(1)REVENUES:Net product revenues$

98,477$

83,951$<
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
2. BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
3. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
4. BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers
5. BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference
6. BioMarin to Present at the Deutsche Bank 2010 BioFEST Conference
7. BioMarin Completes Partial Exchange of Convertible Notes Due 2013 for Common Stock
8. BioMarin Announces Third Quarter 2010 Financial Results
9. BioMarin to Host a Research and Development Day on October 19th
10. BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
11. BioMarin to Present at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... August 3, 2015 BiondVax Pharmaceuticals Ltd. ... analysis of results from a study which demonstrates that BiondVax,s ... trial which took place in 2012, provided participants with increased ... time of the study- in particular the current newly emerged ... the United States in 2015. ...
(Date:8/3/2015)... SAN DIEGO , Aug. 3, 2015  Sorrento ... that it has entered into an exclusive licensing agreement ... or biobetter antibodies from Mabtech Limited, a holding company ... China . Under the ... these 4 monoclonal antibodies (mAbs) for the North American, ...
(Date:7/31/2015)... July 31, 2015  Physicians and payers alone ... biopharmaceutical market. Patients are better informed and getting ... switching therapies. This shift in power is reshaping ... toward patient-focused marketing. As part of ... learned it,s important to educate, communicate and engage ...
Breaking Medicine Technology:Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 2Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 3Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 4Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2
... N.J., July 11, 2011 MonoSol Rx, a ... PharmFilm® technology platform, in collaboration with APR Applied ... that its FDA-approved anti-emetic Zuplenz (Ondansetron) oral soluble ... partners.  The Company made the strategic decision to ...
... YORK, July 11, 2011 Reportlinker.com announces ... available in its catalogue: ... approval brings lessons and hope to market ... To order this report: ...
Cached Medicine Technology:MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners 2MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners 3
(Date:8/3/2015)... ... August 03, 2015 , ... Representatives with Health ... on its website. , “Our ‘Ask a Nutritionist’ feature on our website is a ... healthily,” said Liza Brisk, nutritionist and spokeswoman for Health Food Grocers. , Health Food ...
(Date:8/3/2015)... ... August 03, 2015 , ... The Workgroup for Electronic Data ... IT to create efficiencies in healthcare information exchange, announced the release of its findings ... and Human Services (HHS) Secretary, WEDI shared survey results and recommendations ...
(Date:8/3/2015)... ... ... They know every second counts. And when it comes to stroke, the ... best care in the nation. For the past two months, the stroke team led ... time in the country. During the months of June and July, it took the ...
(Date:8/3/2015)... ... 03, 2015 , ... BESLER Consulting today announced the firm ... The MarketingProfs Bright Bulb B2B Awards celebrate the best marketing, communications, and creative ... of their Readmissions Analytics product was selected as one of four finalists in ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novation, the nation’s largest ... pharmacogenetic lab testing and precision medicine solutions that can help pharmacists and other ... more than 8.6 million adverse drug events are reported in the U.S. ...
Breaking Medicine News(10 mins):Health News:Health Food Grocers Launches "Ask a Nutritionist" Service 2Health News:Health Food Grocers Launches "Ask a Nutritionist" Service 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 4Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 2Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 3Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3
... threeat to the globe as 95% of the AIDS ... General Assembly Special Session on HIV/AIDS, physicians demanded to ... would cater the AIDS victims in developing countries. ... (commonly known as Medicines Sans Frontieres, or MSF), MSF ...
... herbal product ginseng root has a number of psychological ... boosting mood performance. But researchers have found no psychological ... PhD, associate professor and co-director of the sport and ... Corvallis, Oregon and his colleague, Hermann Engles, PhD, conducted ...
... inherited disease of the nervous system due to the ... such as involuntary movements and balance problems and later ... well. ,All these days, until now, it was ... form of the protein 'huntingtin' which is responsible for ...
... bacteria known as E. coli 0157:H7 causes some of ... adults. Infections with this organism are often caused by ... to treat children with E. coli bacterial infection increases ... ,"Our data suggests that antibiotics are not only ...
... go in for strategic alliances among themselves to ... and precluding cut-throat competition which would be detrimental ... the Commerce Secretary, Mr. Prabir Sengupta, at the ... Pharmaceuticals and Cosmetics Export Promotion Council here on ...
... its true , this salient disclosure revealed its truth when ... Dr. Fernando D. Martinez ,According to Dr.Fernando D.Martinez and collegues ... between 6 and 11 years of age have a sevenfold ... any such associated risk of asthma even if they are ...
Cached Medicine News:Health News:Pharma cos must forge Strategic alliances 2
... 1575 immunowash microplate washer ... needle position to perform ... maximize wash efficiency. This ... choice of wash that ...
... LMW Automated Microplate ... choice for any laboratory. ... sensor allows a precise ... residual volume, digitally controlled ...
... ELx50 is a fast and versatile automated strip ... manifold. It is a self contained and programmable ... fluidic delivery from the gentle dripping of a ... pressure delivery systems. ELx50/12V processes 1 x 12 ...
... The Microplate washer MP-1200 is ... microplate washing system. Its internal micropumps ... and to discharge from all types ... microplate to be washed in rows ...
Medicine Products: